黑龙江省人民政府办公厅印发《黑龙江省支持生物制造产业高质量发展若干政策措施》，其中提到，支 持生物制造项目建设。面向生物医药、生物化工、生物农业等重点领域，支持创新水平高、产业带动性 强、具有重大突破性的产业化项目建设。对生物制造领域新建（不含改建、扩建、技术改造）固定资产 投资2000万元（含）以上的高新技术产业化项目，按照核定固定资产投资的20%给予补助，单个项目最 高补助5000万元。推荐符合条件的项目争取中央预算内投资、超长期特别国债等资金支持。 ...

Core Viewpoint - The Heilongjiang Provincial Government has issued a set of policy measures to support the high-quality development of the biomanufacturing industry, aiming to enhance technological innovation, promote industrial expansion, and ensure resource allocation to create competitive advantages and seize future development opportunities [2][7]. Group 1: Enhancing Technological Innovation - Support for the construction of innovation platforms in biomanufacturing through collaboration between enterprises and research institutions, with financial rewards for approved national and provincial platforms [3][8]. - Encouragement for tackling core technological challenges in biomanufacturing, with provincial financial support for approved key research projects [3][8]. - Incentives for enterprises to increase R&D investment, with subsidies for qualifying expenditures exceeding 500,000 yuan, matched by provincial and municipal funding [3][8]. - Support for the establishment of pilot testing and verification platforms, with potential subsidies of up to 1 million yuan based on performance evaluations [3][8]. - Promotion of technology transfer activities, providing funding for contracts exceeding 1 million yuan for technology purchases from research institutions [3][8]. Group 2: Promoting Industrial Expansion and Quality Improvement - Financial support for new biomanufacturing projects in key sectors, with subsidies of up to 5 million yuan for fixed asset investments of 20 million yuan or more [4][9]. - Assistance for equipment upgrades in biomanufacturing enterprises to enhance production efficiency and reduce costs [4][9]. - Support for digital transformation using AI, big data, and IoT technologies, with subsidies for recognized digital workshops and smart factories [4][9]. Group 3: Supporting Key Sector Development - Focus on strengthening the biopharmaceutical sector with financial support for clinical trials and production of new drugs and high-end medical devices, with potential rewards of up to 1.5 million yuan [4][9]. - Encouragement for the development of new food products, with one-time rewards for approved new food materials and additives [4][9]. - Promotion of biochemicals with high added value, providing rewards for significant sales achievements in new products [4][9]. Group 4: Resource Allocation and Financial Support - Support for the construction of biomanufacturing parks and infrastructure, with potential bond funding for qualifying projects [5][10]. - Inclusion of biomanufacturing enterprises in key resource allocation for utilities, ensuring priority in energy supply [5][10]. - Financial services support for biomanufacturing enterprises to facilitate listing and access to capital markets, including innovative loan products [5][10]. Group 5: Intellectual Property and Talent Development - Strengthening intellectual property protection for biomanufacturing innovations, with services to expedite patent applications [10][11]. - Encouragement for educational institutions to develop relevant programs and attract high-level talent to the biomanufacturing sector [10][11]. Implementation Timeline - The policy measures are effective from the date of issuance until December 31, 2028, with provisions for adjustments based on national and provincial policy changes [10].

（来源：嘉兴日报） "不敢说能为家乡带来多少直接投资，但我会利用自己的身份，多多促成嘉兴与德国莱茵—美因地区之 间商业代表团的互访。"从海盐澉浦走出的"村娃子"袁袭，在德国创业生活20余载，却始终乡音未改。 作为拥有300多家企业会员的商业俱乐部亚洲事务主管，她惦念的不仅是家乡"炒雪冬"的乡土滋味，更 是如何让家乡的企业走向世界，让世界的资本看见嘉兴。 活动伊始，嘉兴市商务局、市投资促进中心相关负责人便为乡贤们送上了一份厚重的"家乡发展报告"。 报告不仅细数了嘉兴经济社会发展的最新成果，更重磅推介了以新材料、新一代网络通信、智能光伏、 新能源汽车及零部件为核心的"135N"现代产业体系。面对新一轮科技革命，嘉兴已然在人工智能、临 空经济等新兴赛道上提前布局，展现出强大的产业韧性与未来潜力。 "每次回来，都能感受到嘉兴的更新和变化。"从嘉兴一中毕业走出去的郁虹刚，亲身经历了中国制造的 辉煌十年，如今转身为投资人，他对家乡产业的蝶变升级感触尤深。正是家乡这份扎实的产业底气和清 晰的战略眼光，让他毫不犹豫地作出了"优先选择家乡"的承诺。 活动的重头戏是"嘉兴市招商合作大使"的聘任仪式。9位来自航空航天、投资金融、生 ...

瑞普生物做LP 导读： 上市公司密集设立并购基金，又一家LP入场。 作者丨黄蓉 时隔一年，瑞普生物又出手了。 2月12日，瑞普生物发布公告，称公司与海通并购（上海）私募基金管理有限公司、 海通开元投 资有限公司、高邮市产业引导基金（有限合伙）及关联方天津瑞晟私募基金管理有限公司签署《江 苏国泰海通瑞普并购产业基金合伙企业（有限合伙）之合伙协议》，拟共同出资设立江苏国泰海通 瑞普并购产业基金合伙企业（有限合伙）。 根据公告，该基金总规模为人民币10亿元。其中，瑞普生物作为有限合伙人以自有资金及自筹资 金出资人民币2.95亿元，占合伙企业认缴出资总额的 29.50%。 此外， 作为有限合伙人， 海通开元出资2.05亿元，占认缴出资总额20.5%。高邮市产业引导基 金认购4.9亿元，占比49%。海通并 购（上海）私募基金管理有限公司作为基金普通合伙人和执 行事务合伙人，与 天津瑞晟私募基金管理有限公司各认缴500万元，占比0.5% 本基金投资期为5 年，退出期为2年。退出期后仍有存续项目的， 经合伙人会议同意可延长， 每 次不超过一年，最多不超过一次。 从投资方向看，此次产业并购基金主要以支持实体产业发展为导向，重 ...

免责声明：本文内容与数据由观点根据公开信息整理，不构成投资建议，使用前请核实。 观点网讯：南京诺令生物科技股份有限公司于2月13日向港交所主板递交上市申请，独家保荐人为建银 国际。根据公开资料整理，诺令生物专注于一氧化氮吸入（iNO）疗法的研发与商业化应用。 依托气液精密控制技术平台，诺令生物已建立起覆盖一氧化氮发生、传输、检测、储存和临床应用的全 链路技术能力，是全球少数实现该技术自主可控的企业之一。 ...

Core Viewpoint - Jiangsu Pulaim Pharmaceutical Co., Ltd. has officially submitted its listing application to the Hong Kong Stock Exchange on February 13, with CITIC Securities acting as the sole sponsor [1] Company Summary - Pulaim Pharmaceutical is headquartered in Jiangsu and aims to complete its listing within the year, potentially becoming another mainland biopharmaceutical company to go public in Hong Kong [1]

Core Findings - In January 2026, a total of 22 Chinese companies successfully completed IPOs across A-shares, Hong Kong, and US markets, raising a total of 42.839 billion yuan, with A-share IPO numbers halving compared to the previous month [7][8] - The number of IPOs decreased by 26.67% year-on-year and by 50% month-on-month, while the total amount raised increased by 2.17 times year-on-year but decreased by 21% month-on-month [8] - The Hong Kong Stock Exchange led in both the number of IPOs (12 companies) and the amount raised (33.717 billion yuan) [8] A-share Market Analysis - In January 2026, 9 Chinese companies went public in the A-share market, with a 25% year-on-year decrease and a 50% month-on-month decrease in IPO numbers [16] - The total amount raised in the A-share market was 9.053 billion yuan, reflecting a 27.47% year-on-year increase but a 71.18% month-on-month decrease [16] - The highest fundraising in the A-share market was achieved by Zhenstone Co., Ltd., which raised 2.919 billion yuan [16] Hong Kong Market Analysis - The Hong Kong market saw 12 IPOs in January 2026, with a 50% year-on-year increase but a 52% month-on-month decrease [18] - The total amount raised in Hong Kong was 33.717 billion yuan, marking a 5.62 times year-on-year increase and a 48.49% month-on-month increase [18] - The presence of AI-related companies in the IPOs indicates a significant investment interest from VC/PE institutions in the sector [18] US Market Analysis - Only 1 Chinese company completed an IPO in the US market in January 2026, representing a 90% year-on-year decrease [21] - The amount raised in the US was 0.07 billion yuan, a 94.71% year-on-year decrease [21] - Recent SEC policy changes are expected to further impact small companies' ability to go public in the US [21] VC/PE Exit Analysis - In January 2026, 13 companies with VC/PE backing went public, a 13.33% year-on-year decrease and a 62.86% month-on-month decrease [26] - The total exit return for VC/PE institutions was 109.455 billion yuan, a 15.3 times year-on-year increase [26] - The electronic information sector had the highest exit returns, with notable contributions from companies like Zhiyuan and Biran Technology [26] Industry and Regional Analysis - The electronic information sector led in both the number of IPOs and the amount raised, with 7 companies raising a total of 26.595 billion yuan [34] - Shanghai had the highest number of IPOs (5 companies) and the highest amount raised (18.384 billion yuan) [40] - The fundraising amount from Shanghai increased by 165.61 billion yuan year-on-year, the largest increase among regions [40] Key IPO Cases - The top fundraising companies included Biran Technology (5.017 billion yuan), MiniMax (4.318 billion yuan), and Haowei Group (4.297 billion yuan) [48] - The highest market capitalization on the first day was recorded by Haowei Group at 150.833 billion yuan [49]

公司状况 公司此前公告的回购计划(期限为2024年10月31日起12个月内)可能已接近尾声或完成，但无最新进展更 新。公司作为国家级专精特新"小巨人"企业，持续探索AI技术在研发中的应用，这些是长期关注点。 以上内容基于公开资料整理，不构成投资建议。 经济观察网药康生物(688046.SH)近期披露2025年度业绩快报，显示营业收入同比增长15.49%至7.93亿 元，归母净利润同比增长31.49%至1.44亿元。公司2025年年度报告即将正式发布，将提供更详细的财务 和经营数据。 业绩经营情况 公司已于2026年2月3日披露2025年度业绩快报，显示营业收入同比增长15.49%至7.93亿元，归母净利润 同比增长31.49%至1.44亿元。根据证券之星的报道，2025年年度报告即将正式发布，这将提供更详细的 财务和经营数据。 ...

经济观察网截至2026年2月13日收盘，星昊医药(代码：920017)股价为18.70元，当日下跌0.58%。近5日 累计跌幅为1.89%，近20日跌幅为3.16%，表现弱于大盘(同期上证指数跌1.26%)。资金面上，2月13日生 物医药板块主力资金净流出13.43亿元，可能对个股情绪形成拖累。此外，2月12日融资买入额为91.80万 元，融资余额为4579.69万元，显示部分资金短期参与。 以上内容基于公开资料整理，不构成投资建议。 ...

据决策杂志消息，2月12日，合肥市肥东县正式发布，2025年全县地区生产总值达到1001.3亿元，增长 6.5%。2025年，肥东县社会消费品零售总额增长7.8%。汽车是肥东县消费市场的支柱产业，全年汽车 零售额达127.9亿元，同比增长24%，其中新能源汽车零售额102亿元，同比增长49.9%。 对比周边，以2024年的数据来看，江苏县域生产总值为52208.51亿元，浙江县域生产总值为38858.92亿 元，分别是安徽县域的2.1倍、1.61倍。与中部其他地区相比，2024年河南县域生产总值为32694.98亿 元，湖南县域生产总值为33778.21亿元，分别是安徽县域的1.36倍、1.4倍。 今年安徽省两会期间，安徽省省长王清宪参加省政协十三届四次会议民革、民建、经济界联组会，主题 正是"推动县域经济高质量发展"。王清宪指出，要走好创新驱动、晚起步高起点的路子，紧扣主导产业 需求，持续捕捉、对接和导入创新资源，在科技创新和产业创新深度融合中提升产业竞争力。 着眼未来五年，安徽"十五五"规划建议中也提到，要持续壮大县域经济。支持基础好、潜力大的县 （市）冲刺千亿级经济总量。优化县域特色产业集群布局，构建农 ...